Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Cash from Operations data on record, last reported at 92901000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 38.93% year-over-year to 92901000.0; the TTM value through Dec 2025 reached 377922000.0, down 64.18%, while the annual FY2025 figure was 377922000.0, 64.18% down from the prior year.
  • Cash from Operations reached 92901000.0 in Q4 2025 per CRNX's latest filing, up from 110718000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13543000.0 in Q1 2022 and bottomed at 110718000.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 49025350.0, with a median of 41072500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: surged 32.51% in 2022, then tumbled 200.66% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 22899000.0 in 2021, then tumbled by 53.75% to 35207000.0 in 2022, then fell by 15.9% to 40806000.0 in 2023, then tumbled by 63.88% to 66871000.0 in 2024, then crashed by 38.93% to 92901000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 92901000.0 in Q4 2025, 110718000.0 in Q3 2025, and 85851000.0 in Q2 2025.